Google
Precision BioSciences: FDA Grants Orphan Drug Designation For PBGENE-DMD
(RTTNews) - Precision BioSciences (DTIL) announced the FDA has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy. PBGENE-DMD was recently granted FDA Rare Pediatric Disease designation for the treatment of DMD.
Cindy Atwell, Chief Development and Business Officer at Precision BioSciences, said: "Looking ahead, we remain in active dialogue with the FDA as we advance PBGENE-DMD toward regulatory milestones, with clinical data anticipated in 2026."
Shares of Precision BioSciences are up 6% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
